Skip to main content
UK clinical trials - updated daily from ClinicalTrials.gov
TrialConnect
← Back to Search
Looking for participantsN/A

ChemoINTEL Assay Algorithm Development Study: In-Vitro Cytotoxic Drug Induced Apoptosis Correlation with Patient Clinical Response to Administered Chemotherapy in Patients

Sponsor: Pierian Biosciences

NCT ID: NCT06844136

View on ClinicalTrials.gov ↗

At a glance

What the study gets you
Health checks and monitoring — no treatment given
Type of study
Observational (no treatment given)
Time in hospital
In-person visits at study sites — visit count not specified by the sponsor
Drug or intervention
No intervention (other)
How long the study runs
Study runs about 44 months (dates as stated)
About the drug or intervention
No intervention — other: No intervention
Patient visit burden
Not specified by the sponsor
Type of study
Observing health over time
Ages
18 Years and over
Who
Female
Number of participants
100
Started
2023-11-22
Last checked
2025-02

Plain English Summary

What is this study?

  • • Testing a new treatment for ovarian cancer
  • • Clinical study - 100 participants
  • • This is a prospective, non-randomized, observational, clinical development study

Who can take part?

  • • Ages 18 Years and over
  • • Diagnosed with ovarian cancer
  • • Female only

Where?

  • • Liverpool - Liverpool Women's NHS Foundation Trust

This is a simplified summary. Always discuss with your doctor before making any decisions.

About This Trial

This is a prospective, non-randomized, observational, clinical development study. Pierian Biosciences is utilizing ChemoINTEL and ImmunoINTEL assay measurements in human tumour cells from patients with advanced stage epithelial ovarian cancer (EOC) to develop a mathematical algorithm which will be able to predict a patient's tumour's sensitivity to specific chemotherapy drugs. The study involves using a sample of tumour biopsy taken during standard of care surgery, with a matched blood sample if possible. Medical history, pathology information and information on chemotherapy for up to 6 cycles will be requested. The information will then be used to developed an algorithm to predict tumour sensitivity to treatment.

More detail

The justification for this study is to provide evidence based predictive scoring of available cytotoxic drug based on the patient's own tumour response characteristics to guide the physician's therapeutic selections and enable a personalized treatment plan. This study will generate a predictive algorithm using individual patient tumour ChemoINTEL and ImmunoINTEL assay response metrics paired with the patient's clinical response data. Subsequent Clinical Validation and Clinical Utility Studies will be conducted to provide further evidence for utilization of personalized predictive response scoring of available therapeutics enabling section of personalized treatment regiments based on each patient's unique tumour as an improvement over guideline driven approaches. Cancer treatments and selection of cytotoxic drugs used in different situations continues to be guideline driven. These selections are generally based on treatment protocols developed as a result of large, population-based, prospective, randomized, multicenter, well-controlled phase 3 studies that analyze treatment outcomes (progression-free survival \[PFS\] and overall survival \[OS\]) as a function of treatment received by patient cohorts. This approach was necessitated by the stark reality that no "predictive" or "treatment-directing" diagnostic technologies were available, a circumstance that, to an overwhelming degree, remains unaltered. Treatment "guidelines" are utilized by most oncologists globally as they recommend treatment algorithms and options based on data with the highest levels of evidence. Several treatment guidelines are available globally such as those produced by the National Comprehensive Cancer Network (NCCN), the American Society of Clinical Oncology (ASCO), and European Society of Medical Oncology (ESMO). These guidelines provide evidence-based recommendations to guide physicians and outline appropriate methods of treatment and care. The guidelines often address specific clinical situations (disease oriented) on the use of approved medical products, procedures, or tests (modality oriented).

Ovarian Cancer

How this trial compares with your answers

Answer 2 more questions to improve match

What we know so far

Condition· Matched your search
Age· Tell us your age for better matching
Gender· Tell us your sex for better matching

Still need:

  • • Tell us your age for better matching
  • • Tell us your sex for better matching

Preliminary match based on your answers. Full eligibility requires on-site assessment including medical history, physical exam, and lab tests. This does not guarantee enrolment.

Eligibility at a Glance

Key info

  • Age: 18 Years and over
  • Who can join: Female only

Biomarkers mentioned

CA-125

What the study is looking for

  • ✓Females ≥18 years of age
  • ✓Diagnosis by pathology of one of either advanced stage EOC, Primary Peritoneal Carcinomatosis, or Fallopian Tube...
  • ✓Newly diagnosed
  • ✓Recurrent
  • ✓Patient provided an evaluable tumor or peritoneal fluid specimen prior to initiating drug treatment for ChemoINTEL...

Who cannot take part

  • ✗Patient has not signed an ICF to participate in a clinical investigation
  • ✗Patient has a cancer other than advanced stage EOC
  • ✗Patient did NOT receive SOC drug treatment, single agents or combination treatment from the indicated list above.
See the full criteria
Screening Criteria: * Females ≥18 years of age * Patient must sign an Informed Consent Form * Patient is suspected to have one of the following * advanced stage Epithelial Ovarian Cancer (EOC) * advanced stage Primary Peritoneal Carcinomatosis * advanced stage Fallopian Tube Carcinoma Inclusion Criteria: * Females ≥18 years of age * Diagnosis by pathology of one of either advanced stage EOC, Primary Peritoneal Carcinomatosis, or Fallopian Tube Carcinoma * Newly diagnosed * Recurrent * Patient provided an evaluable tumor or peritoneal fluid specimen prior to initiating chemotherapy for ChemoINTEL assay analysis * Patient received at least 3 cycles of standard of care chemotherapy for advanced stage EOC with single agent or combination of drugs summarised as below, following biopsy OR surgical resection * Carboplatin * Cisplatin * Cyclophosphamide-4HC active metabolite * Docetaxel * Doxorubicin * Etoposide * Fluorouracil * Gemcitabine * Ifosfamide-4HI active metabolite * Irinotecan * Oxaliplatin * Paclitaxel * Pemetrexed * Topotecan * Vinorelbine * Bevacizumab (Avastin) * Patients will have an appropriate evaluation after their third cycle and sixth cycle of SOC chemotherapy to document response by either RECIST 2009 v1.1, CA-125 KELIM Scoring, and/or circulating tumor DNA longitudinal monitoring * Patient signed Informed Consent Form Exclusion Criteria: * Patient has not signed an ICF to participate in a clinical investigation * Patient has a cancer other than advanced stage EOC * Patient did NOT receive SOC chemotherapy, single agents or combination treatment from the indicated list above. * Patients did NOT have sufficient viable cells recovered from either a fresh tumor dissociation or peritoneal fluid specimen collected prior to initiating chemotherapy available for the minimum ChemoINTEL assay analysis of Carboplatin, Cisplatin, Docetaxel, and Paclitaxel test conditions

Where Is This Study? (1 UK site)

Liverpool Women's NHS Foundation Trust

Liverpool L8 7SS, United Kingdom

Recruiting
Site contact (verified)
Mohamed Mehasseb, MBBCh, MSc, MD, MRCOG, PhDmohamed.mehasseb@lwh.nhs.uk

How to Get in Touch

Norman Purvis, PhD

Sponsor contact

CONTACT

+44 (0)333 034 1690 npurvis@pierianbio.com

Maria Maguire, PhD

Sponsor contact

CONTACT

07824609720 maria.maguiire2@nhs.net
Data sourced from ClinicalTrials.gov · Last verified: 2025-02